James Short of Celadon Pharmaceuticals discusses their business strategy and operational progress
Episode 776, Jul 01, 2022, 11:40 AM
James Short, CEO of Celadon Pharmaceuticals #CEL, a UK-based pharmaceutical company focused on the development and supply of natural, cannabis-based medicines, provides an update on its business strategy and operations.
James Short, CEO of Celadon Pharmaceuticals #CEL, a UK-based pharmaceutical company focused on the development and supply of natural, cannabis-based medicines, provides an update on its business strategy and operations.
Highlights
§ Successfully completed sixth harvest from its Phase 1 grow facility, with initial results from the selected test batches showing high quality, consistent growing of pharmaceutical grade, high THC medical cannabis
§ Nearing completion of all preparatory work ahead of GMP inspection by MHRA, having undertaken extensive internal audits and independent third-party testing
§ High level of new patient enquiries to LVL clinic for participation in the chronic pain study, with feedback from initial patients reporting improvements in quality of life
§ Phase 2 grow facility build on track and expected to become operational in Q1 2023, following which the Company will aim to expand its high THC medical cannabis grow capacity to three tonnes per year